Volume 19, Issue 6, June 2019, Page 19-21.

Volume 19, Issue 10, October 2019, Page W5-W8.

Volume 19, Issue 6, June 2019, Page 44-46.

Volume 19, Issue 6, June 2019, Page 28-29.

Volume 19, Issue 6, June 2019, Page 30-31.

Volume 19, Issue 6, June 2019, Page 42-44.

Earl (2019) argues that the current uniform restriction of innovative practice limits clinicians’ ability to provide optimal treatment and stunts progress in medicine. We agree that it is important...

Volume 19, Issue 6, June 2019, Page 34-36.

Medical practice is ideally based on robust, relevant research. However, the lack of disease-modifying treatments for Alzheimer’s disease has motivated “innovative practice” to improve patients’ well-being despite insufficient evidence for the regular use of such interventions in health systems treating millions of patients. Innovative or new non-validated practice poses at least three distinct ethical questions: first, about the responsible application of new non-validated practice to individual patients ; second, about the way in which data from new non-validated practice are communicated (...) via the scientific and lay press ; and third, about the prospect of making new non-validated interventions widely available before more definitive testing. We argue that the authors of metabolic enhancement protocols for Alzheimer’s disease have overstated the evidence in favor of these interventions within the scientific and lay press, failing to communicate weaknesses in their data and uncertainty about their conclusions. Such unmeasured language may create false hope, cause financial harm, undermine informed consent, and frustrate the production of generalizable knowledge necessary to face the societal problems posed by this devastating disease. We therefore offer more stringent guidelines for responsible innovation in the treatment of Alzheimer’s disease. (shrink)

Volume 19, Issue 6, June 2019, Page 22-25.

Volume 19, Issue 6, June 2019, Page 36-38.

Volume 19, Issue 6, June 2019, Page 25-27.

Advancements in fetal assessment and therapeutic intervention in medical practice and clinical research call for corresponding progress in regulatory and ethical guidance. In “A new ethical framewo...

Volume 19, Issue 6, June 2019, Page 32-34.

Volume 19, Issue 6, June 2019, Page 1-3.